Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
International Journal of Cancer
|
February 18, 2011
Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer
Ninke Leffers, Renee Vermeij, Baukje-Nynke Hoogeboom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2007
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7
Annechien J A Lambeck, Anne P G Crijns, Ninke Leffers, et al.
Molecular Pharmaceutics
|
September 10, 2010
Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine
Mateusz Walczak, Arjan de Mare, Annelies Riezebos-Brilman, et al.
International Journal of Cancer
|
December 15, 2005
Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia
Jeroen Visser, Debbie van Baarle, Baukje Nynke Hoogeboom, et al.
International Journal of Cancer
|
April 7, 2007
P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy
Annechien Lambeck, Ninke Leffers, Baukje-Nynke Hoogeboom, et al.
International Journal of Cancer
|
December 6, 2011
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study
Renee Vermeij, Ninke Leffers, Baukje-Nynke Hoogeboom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2025
Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Anneke L Eerkens, Martha D Esajas, Koen Brummel, et al.
Oncotarget
|
September 22, 2016
CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy
Fenne L Komdeur, Maartje C A Wouters, Hagma H Workel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 20, 2015
Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer
Maartje C A Wouters, Fenne L Komdeur, Hagma H Workel, et al.
International Journal of Cancer
|
July 22, 2009
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial
Ninke Leffers, Annechien J A Lambeck, Marloes J M Gooden, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
International Journal of Cancer
|
February 18, 2011
Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer
Ninke Leffers, Renee Vermeij, Baukje-Nynke Hoogeboom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2007
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7
Annechien J A Lambeck, Anne P G Crijns, Ninke Leffers, et al.
Molecular Pharmaceutics
|
September 10, 2010
Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine
Mateusz Walczak, Arjan de Mare, Annelies Riezebos-Brilman, et al.
International Journal of Cancer
|
December 15, 2005
Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia
Jeroen Visser, Debbie van Baarle, Baukje Nynke Hoogeboom, et al.
International Journal of Cancer
|
April 7, 2007
P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy
Annechien Lambeck, Ninke Leffers, Baukje-Nynke Hoogeboom, et al.
International Journal of Cancer
|
December 6, 2011
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study
Renee Vermeij, Ninke Leffers, Baukje-Nynke Hoogeboom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2025
Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Anneke L Eerkens, Martha D Esajas, Koen Brummel, et al.
Oncotarget
|
September 22, 2016
CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy
Fenne L Komdeur, Maartje C A Wouters, Hagma H Workel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 20, 2015
Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer
Maartje C A Wouters, Fenne L Komdeur, Hagma H Workel, et al.
International Journal of Cancer
|
July 22, 2009
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial
Ninke Leffers, Annechien J A Lambeck, Marloes J M Gooden, et al.
Page
of 9